Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

Why Investors Are Watching Nanosonics (ASX: NAN) After a Strong Earnings Surge

Is CORIS the Catalyst for Nanosonics’ (ASX: NAN) Next Phase of Expansion? Nanosonics (ASX: NAN) has caught the market’s attention, with its share price climbing 14 percent over the past week as excitement built ahead of its full-year results. The earnings release did not disappoint, giving investors fresh confidence in the company’s long-term growth story. At…

ByCharlie YouldenAugust 26, 2025

4 reasons why Pro Medicus (ASX:PME) just keeps rising to new heights

Another reporting season, another impressive result from Pro Medicus (ASX:PME). Eerily similar to the debate going on about CBA (ASX:CBA), investors debate about whether or not it is overvalued or undervalued, but the share price just keeps going up. We are not going to state our view on where it is headed next, although we…

ByNick SundichAugust 25, 2025

Is the Market Missing Telix’s Long-Term Potential after 63% Revenue Growth?

Telix Pharmaceuticals: Controversy, Growth, and the Road Ahead Every investor knows the uneasy feeling of watching a stock fall, not because of poor earnings, but because of controversy. That is the position Telix Pharmaceuticals (ASX: TLX) finds itself in today. After headlines about an FDA subpoena related to how it communicated drug progress to investors,…

ByCharlie YouldenAugust 21, 2025

Argent BioPharma Jumps 86% After Bold AusCann Acquisition

Argent BioPharma Expands with AusCann Deal On August 19, Argent BioPharma (ASX: RGT) announced it was buying AusCann’s assets, which include the 100% ownership of the Neuvis drug delivery platform, 48% of CannPal Animal Therapeutics, and part of 20% of ECC Pharm. This deal gives Argent new technology, more research data, and access to the…

ByCharlie YouldenAugust 19, 2025

CSL FY25 Analysis 14% Profit Growth Despite Slower Revenue Growth

CSL’s Growth Slows, Profits Surge: What Investors Need to Know For decades, CSL Limited (ASX: CSL) has been regarded as one of Australia’s most dependable healthcare giants, the kind of stock you could tuck away and forget. Yet in recent years, even this blue-chip defensive stock has shown it is not immune to market turbulence.…

ByCharlie YouldenAugust 19, 2025

Eli Lilly (NYSE:LLY): This US$700bn company is set to beat Novo Nordisk & Ozempic even with this month’s hiccup

For investors who missed the run in Novo Nordisk shares, Eli Lilly (NYSE:LLY) appeared to be the next best thing. And perhaps those who bought into Eli Lilly would have less regrets with Novo Nordisk shares having shed 60% in the last year and Eli Lilly shares gone well. On a market cap basis, Eli…

ByNick SundichAugust 19, 2025

ASX Health Care Stocks Under Trump: Who’ll Win and Who’ll Lose?

What does the next few years hold for ASX Health Care Stocks Under Trump? There's no doubt that the health care sector is bearing a greater brunt than any other ASX sector. Investors are concerned about tariffs on Australian imports, and the potential for the Pharmaceutical Benefits Scheme to be disrupted. The latter makes medicines available…

ByNick SundichAugust 18, 2025

Merck & Co (NYSE:MRK): Its a top 5 healthcare company, but needs to figure out its post-Keytruda future

Merck & Co (NYSE:MRK) is one of the world's most prominent healthcare companies. The healthcare industry is perceived by many investors to be one of the best industries to invest in because it is resilient to adverse economic conditions, but also offers substantial growth opportunities as new innovations can quickly take off given the impact…

ByNick SundichAugust 15, 2025

Telix SEC Subpoena Explained: Why the Stock Plunged 31%

What Investors Need to Know About the Telix SEC Subpoena What happens when a fast-growing biotech lands a major U.S. listing, then suddenly finds itself in the SEC’s crosshairs? That’s the question Telix Pharmaceuticals (ASX:TLX) investors are now asking after the company disclosed it had received a subpoena from the U.S. Securities and Exchange Commission.…

ByCharlie YouldenAugust 8, 2025

ResMed (ASX:RMD): Investors who bought the dip would be satisfied, but is there any growth left in this one?

ResMed (ASX:RMD) is one of the few ASX healthcare stocks that has successfully made it in the USA. And while Trump's tariffs have caused headaches for many healthcare stocks, ResMed might even be a beneficiary of them. Yes, there was a temporary dip in the share price, but shares are up more than 20% in…

ByNick SundichAugust 5, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Why Investors Are Watching Nanosonics (ASX: NAN) After a Strong Earnings Surge

4 reasons why Pro Medicus (ASX:PME) just keeps rising to new heights

Is the Market Missing Telix’s Long-Term Potential after 63% Revenue Growth?

Argent BioPharma Jumps 86% After Bold AusCann Acquisition

CSL FY25 Analysis 14% Profit Growth Despite Slower Revenue Growth

Eli Lilly (NYSE:LLY): This US$700bn company is set to beat Novo Nordisk & Ozempic even with this month’s hiccup

ASX Health Care Stocks Under Trump: Who’ll Win and Who’ll Lose?

Merck & Co (NYSE:MRK): Its a top 5 healthcare company, but needs to figure out its post-Keytruda future

Telix SEC Subpoena Explained: Why the Stock Plunged 31%

ResMed (ASX:RMD): Investors who bought the dip would be satisfied, but is there any growth left in this one?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here